Aradigm to Hold 2007 First Quarter Financial Results Conference Call May 10
Posted on: Monday, 7 May 2007, 18:00 CDT
Aradigm Corporation (OTCBB: ARDM), a specialty pharmaceutical company, will release its 2007 first quarter financial results after the market close on Thursday, May 10, 2007.
Aradigm's President and Chief Executive Officer Igor Gonda, Ph.D., and Company management will be hosting an investment-community conference call beginning at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) on Thursday, May 10, 2007 to discuss the financial results, provide a business update and to answer questions.
To participate in the live call by telephone, please dial (800) 323-0845 from the U.S., and for international callers, please dial (706) 634-8407. A telephone replay will be available for 48 hours by dialing (800) 642-1687 from the U.S., or (706) 645-9291 for international callers, and entering reservation number 8511497.
Individuals interested in listening to the conference call via the Internet may do so by visiting www.aradigm.com. An archived presentation will be available on the Web site for 14 days.
About Aradigm
Aradigm is an emerging specialty pharmaceutical company focused on the development and commercialization of a portfolio of drugs delivered by inhalation for the treatment of severe respiratory diseases by pulmonologists. Current activities include partnered and self-initiated development programs addressing the treatment of cystic fibrosis, bronchiectasis, pulmonary hypertension, inhalation anthrax infections and smoking cessation.
In addition, Aradigm's AERx insulin Diabetes Management System (iDMS), which has been licensed to Novo Nordisk for development and commercialization in return for royalties, is in Phase 3 testing for Type 1 and Type 2 diabetes. Under the agreements with Novo Nordisk, Novo Nordisk is responsible for all further clinical, manufacturing and commercial development, while Aradigm and Novo Nordisk continue to cooperate and share in technology development, as well as intellectual property development and defense. More information about Aradigm can be found at www.aradigm.com.
Except for the historical information contained herein, this news release contains forward-looking statements that involve risk and uncertainties, including clinical results, the timely availability and acceptance of new products, the impact of competitive products and pricing, the availability of funding from partners or capital markets, and the management of growth, as well as the other risks detailed from time to time in Aradigm Corporation's Securities and Exchange Commission (SEC) Filings, including the company's Annual Report on Form 10-K, and quarterly reports on Form 10-Q.
Aradigm and AERx are registered trademarks of Aradigm.
SOURCE: Aradigm
Source: MARKET WIRE
Related Articles
- Novo Nordisk Appoints Andy Ajello as Vice President for National Diabetes Sales, Managed Care and Government Accounts
- Medarex to Receive Milestone Payment From Novo Nordisk
- Novo Nordisk Changing Diabetes(SM) Bus World Tour Tackles Diabetes Epidemic in Chicago
- Aradigm to Hold 2006 Fourth Quarter Financial Results Conference Call March 29
- Aradigm and Novo Nordisk Execute Further Restructuring of Partnership
- Aradigm Announces Update By Novo Nordisk on AERx Inhaled Insulin Phase 3 Clinical Program
- Model N Software Selected By Novo Nordisk Pharmaceuticals to Manage Medicaid Rebate Program
- Newt Gingrich and Novo Nordisk Join Georgia Business and Health Care Leaders in a Call-to-Action to Combat the Diabetes Epidemic
- Newt Gingrich and Novo Nordisk Join Texas Health Care Leaders in a Call-to-Action Against the Diabetes Epidemic
- Aradigm Expands Financial and Strategic Strength on Closing of Restructured Licensing Agreement With Novo Nordisk
 |
 |
User Comments (0)
RSS Feeds